Metsera, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Metsera, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Metsera, Inc. do? Business model and key facts
Get the full picture of Metsera, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 93
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Stocks related to Metsera, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Metsera, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Metsera, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
